A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
a study on Hemolytic Disease of the Fetus and Newborn
Hemolytic Disease of the Fetus and Newborn M281 HDFN Rhesus Disease Hemolytic disease due to fetomaternal alloimmunization Hemolytic disease of the newborn with Kell alloimmunization Rhesus (Rh) isoimmunization of foetus or newborn Isoimmunization due to other red cell factors ABO isoimmunization of foetus or newborn Haemolytic anaemia due to other unclassified antibodies Isoimmune Isoimmunized Isoimmunization Alloimmune Alloimmunized Alloimmunization Pregnant women Hemolysis
Lead Scientist at UCSF
- Mary Norton
Professor, Ob/Gyn, Reproductive Sciences. Authored (or co-authored) 200 research publications.
- accepting new patients
- Start Date
- Completion Date
- Janssen Research & Development, LLC
- To learn how to participate in this trial please click here.
- Phase 2
- Study Type
- Last Updated